Coexpression Network Analysis Identifies a Novel Nine-RNA Signature to Improve Prognostic Prediction for Prostate Cancer Patients
Table 3
The univariate and multivariate Cox regression analysis to identify independent prognostic factors.
Variables
TCGA ()
Univariate analysis
Multivariate analysis
HR
95% CI
value
HR
95% CI
value
Age (years, )
1.053
0.956-1.160
2.91E-01
—
—
—
Pathologic_M (M0/M1/-)
452/3/39
2.892
0.470-5.366
1.48E-01
—
—
—
Pathologic_N (N0/N1/-)
344/78/72
3.609
0.799-16.30
7.46E-02
—
—
—
Pathologic_T (T2/T3/T4/-)
186/291/10/7
2.242
0.601-8.373
2.27E-01
—
—
—
Radiation therapy (yes/no/-)
59/386/49
2.984
0.577-15.42
2.33E-01
—
—
—
Targeted molecular therapy (yes/no/-)
52/392/50
3.127
0.592-16.52
2.20E-01
—
—
—
Gleason score (6/7/8/9/10)
45/245/63/137/4
2.959
1.337-6.549
2.28E-03
1.685
1.163-3.963
2.32E-02
Prostate-specific antigen
1.062
1.004-1.124
9.60E-05
1.022
1.019-1.054
1.52E-02
Recurrence (yes/no/-)
368/58/68
7.224
1.937-26.94
5.68E-04
2.081
0.424-10.222
3.67E-01
Prognostic score status (high/low)
247/247
9.574
1.212-17.56
5.06E-03
5.846
1.708-18.27
1.01E-02
Death (dead/alive)
10/484
—
—
—
—
—
—
Overall survival days (months, )
—
—
—
—
—
—
SD: standard deviation; TCGA: The Cancer Genome Atlas; HR: hazard ratio; CI: confidence interval. Bold indicated the factors with statistical significance.
